Case study: Baxter Healthcare
Australia’s only local manufacturer of intravenous (IV) fluids is ramping up its operations to support the national response to the COVID-19 pandemic.
Baxter Healthcare has increased its production at its local manufacturing plant in western Sydney to 24/7 in response to the increased demand for IV fluids in the ICU and across the hospital system.
It has also brought on an additional 70 employees across all parts of the business in the past month including senior engineers and technicians.
Baxter is also a major supplier of equipment for the ICU including its Continuous Renal Replacement Therapy (CRRT) devices and infusion pumps.
Baxter Australia and New Zealand General Manager Steven Flynn said the company was working closely with its customers and Federal and State Governments to maintain supply and meet the increased demand.
“As the only manufacturer of these critical IV medicines in Australia, we are committed to supporting our local hospitals and the brave healthcare professionals on the frontline,” Mr Flynn said.
“Given the diversity of Baxter’s portfolio and the medical necessity of our products, we have been able to expand our workforce here in Australia.”
Baxter’s staged pandemic response plan, which follows guidelines from the Centers for Disease Control and the World Health Organization, is active across all facilities globally.
The response plan includes protective measures such as enhanced infection control actions, remote working arrangements for office-based employees, restricted travel, symptom screening at building entrances, and use of personal protective equipment by employees.
Manufacturing operations have also been modified to limit interactions between employee groups.
“We've also been able to leverage our global supply chains and manufacturing operations overseas to bolster our local response to COVID-19,” said Mr Flynn.
“Our workforce continues to step up to the challenges and deliver life-saving medicines and medical devices for clinicians and patients.”
Baxter makes life-saving dialysis products and intravenous fluids for the Oceania market, employs more than 1000 people in Australia and supports a further 1,800 indirect jobs across Australia.
“In challenging times like this, our culture of collaboration and continuous improvement helps us to adjust to the changing needs of our customers, healthcare professionals and the patients they serve.
“We are doing everything we can to make sure our healthcare system and healthcare professionals on the frontline have the equipment, medicines and support they need.
“Everything we do at Baxter comes back to our Mission, to save and sustain lives.”